Journal of Clinical Virology
Volume 47, Issue 1 , Pages 38-42 , January 2010

Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck® HPV-screening assay

  • Philippe Halfon

      Affiliations

    • Hôpital Ambroise Paré, Marseille, France
    • Laboratoire Alphabio, Marseille, France
    • Corresponding Author InformationCorresponding author at: Laboratoire Alphabio, 23 Rue de Friedland, 13006 Marseille, France. Tel.: +33 4 91 25 41 00; fax: +33 4 91 79 20 44.
    • ,
  • Dominique Benmoura

      Affiliations

    • Hôpital Ambroise Paré, Marseille, France
    • ,
  • Hacene Khiri

      Affiliations

    • Laboratoire Alphabio, Marseille, France
    • ,
  • Guillaume Penaranda

      Affiliations

    • CDL Pharma, Marseille, France
    • ,
  • Bernard Blanc

      Affiliations

    • Hôpital Ambroise Paré, Marseille, France
    • ,
  • Daniela Riggio

      Affiliations

    • Laboratory Medicine Unit, European Institute of Oncology, Milano, Italy
    • ,
  • Maria Teresa Sandri

      Affiliations

    • Laboratory Medicine Unit, European Institute of Oncology, Milano, Italy

Received 16 September 2009 ,Revised 23 October 2009 ,Accepted 27 October 2009.

References 

  1. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764–1772
  2. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl. 3):S3 1–10
  3. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening?. Int J Cancer. 2009;
  4. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev. 2008;17:3033–3042
  5. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–632
  6. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579–1588
  7. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101:88–99
  8. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516–520
  9. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol. 2003;201:1–6
  10. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527
  11. Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol Oncol. 2006;103:12–17
  12. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7:11–22
  13. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–350
  14. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346–355
  15. Huang YK, You SL, Yuan CC, Ke YM, Cao JM, Liao CY, et al. Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening. Br J Cancer. 2008;98:863–869
  16. Huang S, Tang N, Mak W, Erickson B, Salituro J, Li Y. Principles and analytical performance of Abbott RealTime High Risk HPV test. J Clin Virol. 2009;45:S13–S17
  17. Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Zerat L, et al. Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests. Sex Transm Dis. 2008;35:521–527
  18. Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods. 2009;156:77–83
  19. Wentzensen N, Schiffman M, Dunn ST, Zuna RE, Walker J, Allen RA, et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer. 2009;124:964–969
  20. Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A. Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol. 2001;65:155–162
  21. Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol. 2006;44:3680–3685
  22. Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, et al. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol. 2007;45:1447–1454
  23. Sandri MT, Lentati P, Benini E, Dell’Orto P, Zorzino L, Carozzi FM, et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol. 2006;44:2141–2146
  24. Stevens MP, Garland SM, Tabrizi SN. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods. 2008;147:290–296
  25. Monsonego J, Bohbot JM, Pollini G, Krawec C, Vincent C, Merignargues I, et al. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol. 2005;99:160–168
  26. Pretet JL, Jacquard AC, Carcopino X, Charlot JF, Bouhour D, Kantelip B, et al. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer. 2008;122:428–432
  27. Pretet JL, Jacquard AC, Saunier M, Clavel C, Dachez R, Gondry J, et al. Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDiTH III study. Gynecol Oncol. 2008;110:179–184

PII: S1386-6532(09)00531-9

doi: 10.1016/j.jcv.2009.10.013

Journal of Clinical Virology
Volume 47, Issue 1 , Pages 38-42 , January 2010

Article Tools

* Image Usage & Resolution